Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22


Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.

Iyer S, Sam FS, DiPrimio N, Preston G, Verheijen J, Murthy K, Parton Z, Tsang H, Lao J, Morava E, Perlstein EO.

Dis Model Mech. 2019 Nov 11;12(11). pii: dmm040584. doi: 10.1242/dmm.040584.


Drug screens of NGLY1 deficiency in worm and fly models reveal catecholamine, NRF2 and anti-inflammatory-pathway activation as potential clinical approaches.

Iyer S, Mast JD, Tsang H, Rodriguez TP, DiPrimio N, Prangley M, Sam FS, Parton Z, Perlstein EO.

Dis Model Mech. 2019 Nov 4;12(11). pii: dmm040576. doi: 10.1242/dmm.040576.


Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.

Lao JP, DiPrimio N, Prangley M, Sam FS, Mast JD, Perlstein EO.

G3 (Bethesda). 2019 Feb 7;9(2):413-423. doi: 10.1534/g3.118.200934.


GEX1A, a Polyketide from Streptomyces chromofuscus, Corrects the Cellular Defects Associated with Niemann-Pick Type C1 in Human Fibroblasts.

Granatosky EA, DiPrimio N, Pickering JRE, Stevens DC, Perlstein EO, Taylor RE.

J Nat Prod. 2018 Sep 28;81(9):2018-2025. doi: 10.1021/acs.jnatprod.8b00314. Epub 2018 Sep 6.


Doing it All - How Families are Reshaping Rare Disease Research.

Ekins S, Perlstein EO.

Pharm Res. 2018 Aug 16;35(10):192. doi: 10.1007/s11095-018-2481-7.


Defects in the Neuroendocrine Axis Contribute to Global Development Delay in a Drosophila Model of NGLY1 Deficiency.

Rodriguez TP, Mast JD, Hartl T, Lee T, Sand P, Perlstein EO.

G3 (Bethesda). 2018 Jul 2;8(7):2193-2204. doi: 10.1534/g3.118.300578. Erratum in: G3 (Bethesda). 2019 Jan 9;9(1):315.


Ten simple rules of live tweeting at scientific conferences.

Ekins S, Perlstein EO.

PLoS Comput Biol. 2014 Aug 21;10(8):e1003789. doi: 10.1371/journal.pcbi.1003789. eCollection 2014 Aug. No abstract available.


Anatomy of the Crowd4Discovery crowdfunding campaign.

Perlstein EO.

Springerplus. 2013 Oct 24;2:560. doi: 10.1186/2193-1801-2-560. eCollection 2013.


Accumulation of an antidepressant in vesiculogenic membranes of yeast cells triggers autophagy.

Chen J, Korostyshevsky D, Lee S, Perlstein EO.

PLoS One. 2012;7(4):e34024. doi: 10.1371/journal.pone.0034024. Epub 2012 Apr 18.


The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast.

Rainey MM, Korostyshevsky D, Lee S, Perlstein EO.

Genetics. 2010 Aug;185(4):1221-33. doi: 10.1534/genetics.110.117846. Epub 2010 May 10.


Harnessing gene expression to identify the genetic basis of drug resistance.

Chen BJ, Causton HC, Mancenido D, Goddard NL, Perlstein EO, Pe'er D.

Mol Syst Biol. 2009;5:310. doi: 10.1038/msb.2009.69. Epub 2009 Oct 13.


Using expression and genotype to predict drug response in yeast.

Ruderfer DM, Roberts DC, Schreiber SL, Perlstein EO, Kruglyak L.

PLoS One. 2009 Sep 4;4(9):e6907. doi: 10.1371/journal.pone.0006907.


Amino acid metabolic origin as an evolutionary influence on protein sequence in yeast.

de Bivort BL, Perlstein EO, Kunes S, Schreiber SL.

J Mol Evol. 2009 May;68(5):490-7. doi: 10.1007/s00239-009-9218-5. Epub 2009 Apr 9.


Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages.

Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC.

Autophagy. 2007 Nov-Dec;3(6):620-2. Epub 2007 Aug 16.


Evolutionarily conserved optimization of amino acid biosynthesis.

Perlstein EO, de Bivort BL, Kunes S, Schreiber SL.

J Mol Evol. 2007 Aug;65(2):186-96. Epub 2007 Aug 7.


Quantifying fitness distributions and phenotypic relationships in recombinant yeast populations.

Perlstein EO, Deeds EJ, Ashenberg O, Shakhnovich EI, Schreiber SL.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10553-8. Epub 2007 Jun 12.


Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.

Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, Rubinsztein DC.

Nat Chem Biol. 2007 Jun;3(6):331-8. Epub 2007 May 7.


Genetic basis of individual differences in the response to small-molecule drugs in yeast.

Perlstein EO, Ruderfer DM, Roberts DC, Schreiber SL, Kruglyak L.

Nat Genet. 2007 Apr;39(4):496-502. Epub 2007 Mar 4.


Revealing complex traits with small molecules and naturally recombinant yeast strains.

Perlstein EO, Ruderfer DM, Ramachandran G, Haggarty SJ, Kruglyak L, Schreiber SL.

Chem Biol. 2006 Mar;13(3):319-27.


Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.

Butcher RA, Bhullar BS, Perlstein EO, Marsischky G, LaBaer J, Schreiber SL.

Nat Chem Biol. 2006 Feb;2(2):103-9. Epub 2006 Jan 15.


A library of spirooxindoles based on a stereoselective three-component coupling reaction.

Lo MM, Neumann CS, Nagayama S, Perlstein EO, Schreiber SL.

J Am Chem Soc. 2004 Dec 15;126(49):16077-86.


Global nucleosome occupancy in yeast.

Bernstein BE, Liu CL, Humphrey EL, Perlstein EO, Schreiber SL.

Genome Biol. 2004;5(9):R62. Epub 2004 Aug 20.

Supplemental Content

Loading ...
Support Center